Uveitis Trial, Completed (NCT04200833)

Uveitis Trial, Completed NCT04200833 Sponsor: Medical University of Graz Condition: Uveitis

Printed from Voxsanity (voxsanity.com.au) — NCT04200833 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Uveitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial (NCT04200833) enrolled 10 participants, all in a single group, and all 10 completed the study with no dropouts. The trial was looking at golimumab (an injection-based medicine) as a treatment for uveitis — a type of eye inflammation. The main thing researchers were measuring was how many participants' eye inflammation reached a "complete response," meaning the inflammation in the front of the eye fully settled down to the lowest possible level. They also tracked vision, eye discomfort, and whether participants were able to reduce their steroid dose over 12 months. The reported data shows that out of the 10 participants, 8 were recorded as "complete responders" — meaning their eye inflammation reached that fully settled level. For vision, the reported average score was 0.27 on the LogMAR scale (a standard way of measuring eyesight, where a lower number generally reflects better vision). The reported data shows that 0 participants reported ocular discomfort such as eye soreness or light sensitivity. Regarding steroid use, the reported data shows an average reduction of 0.19 mg/kg per day in systemic (whole-body) steroid dose at the 12-month point compared to the start of the trial. It is worth noting that this was a very small study of only 10 people, and the data as submitted does not include comparison figures or further statistical detail for some measures. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

View full results on ClinicalTrials.gov ↗

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with uveitis (eye inflammation) that is linked to a condition called Juvenile Idiopathic Arthritis (JIA)
You have already tried a medication called adalimumab, but it did not work well enough for you

Who may not be able to join:

Your eye inflammation (uveitis) is caused by something other than Juvenile Idiopathic Arthritis
You were originally started on adalimumab for reasons unrelated to your eye condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I found the following past clinical trial relevant to my condition, and wanted to raise it with you. It is no longer recruiting, but I wanted to ask whether similar active trials exist, or whether its results are relevant to my care:

Trial: NCT04200833

Sponsor: Medical University of Graz

Phase: Not Applicable

Status: Completed

Condition: Uveitis

More information: https://clinicaltrials.gov/study/NCT04200833

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with uveitis (eye inflammation) that is linked to a condition called Juvenile Idiopathic Arthritis (JIA)
You have already tried a medication called adalimumab, but it did not work well enough for you

Who may not be able to join:

Your eye inflammation (uveitis) is caused by something other than Juvenile Idiopathic Arthritis
You were originally started on adalimumab for reasons unrelated to your eye condition

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Completed

Phase

Not Applicable

Sponsor

Medical University of Graz

Registry

ClinicalTrials.gov

Start date

1 March 2010

Est. completion

1 July 2021

Primary endpoints

Number of Participants Reported as Complete Responders to Golimumab

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov